Noble Capital Markets Research Morning Call

Noble Capital Markets Research Report Friday, February 13, 2026

Companies contained in today’s report:

Alliance Entertainment Holding (AENT)/OUTPERFORM – A Disappointing Quarter, But Profitability and Margin Execution Was Strong
Snail (SNAL)/OUTPERFORM – Noble Virtual Conference Highlights

Alliance Entertainment Holding (AENT/$6.38 | Price Target: $9)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
A Disappointing Quarter, But Profitability and Margin Execution Was Strong
Rating: OUTPERFORM

Softer than expected revenue and adj. EBITDA. Fiscal Q2 revenue of $369.0 million was below our $402.1 million estimate and down from $394.0 million a year earlier. The largest revenue variance appeared to be attributable to the lack of arcade inventory in its gaming division due to the bankruptcy of one of its vendors. Adj. EBITDA of $18.1 million was below our $25.3 million estimate, as a result of higher than expected costs in its licensing business. 

Maintains strong margin dynamics. The company maintained strong gross margins at 12.8%, a 210 basis point improvement year over year, but down from our 16.2% estimate. The gross margin was surprisingly solid when considering the significant revenue shortfall. Margins benefited from favorable product mix, structural improvement and cost discipline. In addition, adj. EBITDA margins improved year over year as well (5.0% vs 4.1%). 

Get the Full Report

Snail (SNAL/$0.58 | Price Target: $3)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. On February 4th,  Heidy Chow, CFO, and Peter Lin, Senior Manager FP&A, presented at the Noble Virtual Conference to the investment community. The presentation highlighted strong engagement on its core franchise and recent releases, a busy 2026 release roadmap, and the advancement of its digital assets strategy. The full presentation is available here.

Strong ARK Engagement. The ARK franchise remains a key driver of engagement and monetization for the company, generating nearly $1 billion in revenue, more than 100 million installs, and 4.2 billion gameplay hours since its release. Management noted that the ARK franchise benefits from a highly active core audience, with 42% of players averaging 380 hours of total gameplay. Furthermore, management noted a 55% paid downloadable content (DLC) conversion rate for ARK, with new content releases driving spikes in player activity.

Get the Full Report

Noble Capital Markets Research Report Thursday, February 12, 2026

Companies contained in today’s report:

E.W. Scripps (SSP)/OUTPERFORM – Enterprise Transformation Plan
EuroDry (EDRY)/OUTPERFORM – Increasing 2026 Estimates; Upgrading Rating to Outperform
Euroseas (ESEA)/OUTPERFORM – Tight Feeder Market Supports Rate Upside; Coverage Strengthens Through 2028
Great Lakes Dredge & Dock (GLDD)/MARKET PERFORM – Going Private At All-Time High
InPlay Oil (IPOOF)/OUTPERFORM – Updating 2025 Estimates; Bond Offering Completed

E.W. Scripps (SSP/$3.64 | Price Target: $10)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Enterprise Transformation Plan
Rating: OUTPERFORM

Transformation plan announced. E.W. Scripps launched an enterprise-wide restructuring targeting $125 million to $150 million of incremental annualized EBITDA by 2028, driven by structural cost actions and revenue yield initiatives leveraging AI, automation, and operational realignment. Management emphasized a shift toward a leaner, startup-like operating model while reaffirming investment in journalism and sales capabilities, setting the framework for detailed execution priorities discussed below.

Execution framework. The company identified major cost buckets across administrative functions, technology consolidation, and process redesign, with modeling work underway to refine savings cadence. Management expects months of operational review before final staffing decisions, maintaining a baseline EBITDA framework near $450 million even under softer demand conditions. Beyond expense controls, leadership highlighted opportunities to improve monetization, which informs the evolving growth strategy outlined next.

Get the Full Report

EuroDry (EDRY/$14.32 | Price Target: $23.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Increasing 2026 Estimates; Upgrading Rating to Outperform
Rating: OUTPERFORM

Increasing FY 2026 estimates. We have increased our FY 2026 revenue, adjusted EBITDA, and adjusted EPS estimates to $60.8 million, $25.5 million, and $2.82, respectively, from $57.3 million, $22.4 million, and $1.46. The upward revisions are driven by higher expected vessel earnings, with our forecast average TCE rate rising to $14,743 from $13,873 previously.

Eurodry’s sweet spot. Eurodry owns and operates vessels in the middle of the size range of dry bulk carriers, or 50,000 to 85,000 dead weight tons (dwt), which present the most flexible employment opportunities. EDRY’s fleet consists of 11 vessels with a total carrying capacity of 766,420 dwt. With two Ultramax vessels of 63,500 dwt each under construction and scheduled for delivery in the second and third quarters of 2027, the total carrying capacity will increase to 893,000 dwt. Growth will be driven by the charter rate environment, coupled with fleet growth. While EDRY continues to renew and modernize its fleet, it expects to acquire and consolidate smaller owners.

Get the Full Report

Euroseas (ESEA/$57.46 | Price Target: $72)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Tight Feeder Market Supports Rate Upside; Coverage Strengthens Through 2028
Rating: OUTPERFORM

New time charter for the EM Spetses. Euroseas Ltd. announced a new time charter for its 1,740 twenty-foot equivalent feeder containership, EM Spetses, for a minimum period of 22 to a maximum period of 24 months, at the option of the charterer, at a gross daily rate of $21,500. The new charter will commence on April 12, 2026, in direct continuation of its present charter, and represents a daily increase of over $3,000 compared to the vessel’s current rate.

Incremental EBITDA with Expanded Coverage. The charter is expected to generate approximately $8.9 million in EBITDA over the minimum term and increase Euroseas’ charter coverage to approximately 87% in 2026, 71% in 2027, and 41% in 2028. The higher rate on the new time charter reflects a tight container market with limited vessel availability. Demand in the feeder segment remains strong as operators secure vessels to meet their requirements.

Get the Full Report

Great Lakes Dredge & Dock (GLDD/$16.95)
Joe Gomes jgomes@noblefcm.com | 561-999-2262
Going Private At All-Time High
Rating: MARKET PERFORM

To Be Acquired. Yesterday, Great Lakes announced a definitive agreement for Saltchuk Resources, Inc. to acquire Great Lakes for $17 per share, in cash, an aggregate equity value of $1.2 billion, and a total transaction value of $1.5 billion. The $17 per share consideration is in line with our $17 price target on GLDD shares. The per share purchase price represents a 25% premium to Great Lakes’s 90-day volume-weighted average price as of February 10, 2026, as well as a 5% premium to the Company’s all-time high closing price.

A Surprise. We are somewhat surprised by the timing as Great Lakes has substantially completed its new build program and should begin to generate substantial amounts of free cash flow that could be used to repay outstanding debt, repurchase shares, or grow the business. Nonetheless, shareholders are receiving a premium to the shares’ all-time high closing price.

Get the Full Report

InPlay Oil (IPOOF/$11.4 | Price Target: $15.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Updating 2025 Estimates; Bond Offering Completed
Rating: OUTPERFORM

Q4 2025 Estimate Revisions. We are adjusting Q4 estimates to reflect softer commodity pricing, with WTI averaging $59.10 per barrel versus our prior $60.00 estimate and wider differentials reducing realized Canadian pricing. We are lowering our revenue, adjusted funds flow (AFF), and AFF per share estimates to C$80.7 million, C$29.1 million, and C$1.04, respectively, from C$88.8 million, C$35.8 million, and C$1.28. Our production estimate remains unchanged at 19,419 boe/d.

FY 2025 Estimate Revisions. We are modestly lowering our full-year revenue, AFF, and AFF per share estimates to reflect lower fourth-quarter estimates. We now forecast revenue of C$290.6 million, AFF of C$112.9 million, and AFF per share of C$4.58, down from C$298.7 million, C$119.5 million, and C$4.85, respectively. Our outlook continues to assume average 2025 production of approximately 17,000 boe/d. We will update our 2026 estimates following the release of InPlay’s 2026 guidance.

Get the Full Report

Noble Capital Markets Research Report Wednesday, February 11, 2026

Companies contained in today’s report:

Aurania Resources (AUIAF)/OUTPERFORM – A Growing Portfolio of Precious Metals and Critical Mineral Projects
DLH Holdings (DLHC)/OUTPERFORM – First Quarter 2026 Results
Townsquare Media (TSQ)/OUTPERFORM – Noble Virtual Conference Highlights

Aurania Resources (AUIAF/$0.11 | Price Target: $0.3)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
A Growing Portfolio of Precious Metals and Critical Mineral Projects
Rating: OUTPERFORM

Advancing a multi-project portfolio. Auraniais advancing two projects in France: a gold exploration project in Brittany and a nickel recovery project in Corsica. Aurania is also evaluating the recovery of nickel and cobalt from the waste tailings of the former Balangero asbestos mine near Turin, Italy. The projects in Corsica and Italy offer significant environmental benefits for the nearby communities, along with the economic benefit of recovering valuable critical metals. In Ecuador, the company is having productive discussions with government officials to advance its project while pursuing potential strategic partnerships.

Exploration Licenses in Brittany. Aurania, through a wholly owned French subsidiary, was granted three exploration licenses for polymetallic metals, including gold, in the Brittany Peninsula of northwestern France. The three license areas, Epona, Taranis, and Belenos, are in southern Brittany and northern Pays de la Loire in France. Aurania is in the process of identifying all the landowners to seek their support for exploration. 

Get the Full Report

DLH Holdings (DLHC/$5.56 | Price Target: $10)
Joe Gomes jgomes@noblefcm.com | 561-999-2262
First Quarter 2026 Results
Rating: OUTPERFORM

1Q26 Results. DLH reported revenue of $68.9 million, down from $90.8 million y-o-y, and modestly below our $70.1 million projection. The decline reflects the loss of certain programs to small business set-aside contractors. Adjusted EBITDA was $6.5 million versus our $6.2 million estimate. Net loss was $1.3 million, or a loss of  $0.09/sh, versus our estimate of a loss of $1 million, or a loss of 0.07/sh.

Cost Scaling Initiatives. With the loss of the Head Start program and winding down of the CMOP contracts in 2026, DLH undertook some cost reduction measures in the first and second fiscal quarters to align expenses with current revenue volumes. We expect management to closely watch expenses until top line improvement returns.

Get the Full Report

Townsquare Media (TSQ/$7.18 | Price Target: $15)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. On February 4th, Bill Wilson, CEO, Stu Rosenstein, co-founder and CFO, and Claire Yenicay, EVP of IR, participated in a fireside chat at the Noble Virtual Conference. The discussion focused on the company’s successful evolution into a digital-first local media powerhouse, sustainable financial model and improving revenue trends. A replay of the presentation can be found here.

Favorable Digital Advertising Outlook. Digital advertising trends are stabilizing, with management noting sequential page view growth from December to January, which is expected to continue in February. While remnant inventory remains a near-term headwind, underlying growth in owned-and-operated sales and core programmatic activity remains strong. Management expects digital advertising to return to mid-single-digit growth in 2026, with a high-single-digit CAGR anticipated over the next five years.

Get the Full Report

Noble Capital Markets Research Report Tuesday, February 10, 2026

Companies contained in today’s report:

The Beachbody Company (BODI)/OUTPERFORM – Noble Virtual Conference Highlights

The Beachbody Company (BODI/$9.99 | Price Target: $15)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. On February 5th, the company presented at the Noble Virtual conference. The presentation conducted by Carl Daikeler, Co-founder and CEO, Mark Goldston, Executive Chairman, and Brad Ramberg, CFO, highlighted the completion of a multi-year operational turnaround and favorable growth drivers in its digital fitness and nutrition businesses. A replay of the presentation can be viewed here

Operational turnaround. Over the past several years, the company has significantly lowered its break-even point from $900 million in 2022 to roughly $180 million today, driven largely by SG&A optimization and the elimination of multi-level marketing sales costs. The new model offers enhanced operating leverage, enabling profitability at lower revenue levels and improving the long term outlook of the company.

Get the Full Report

Noble Capital Markets Research Report Monday, February 9, 2026

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – January Ethereum Metrics
Graham (GHM)/MARKET PERFORM – FY3Q26 Results
Seanergy Maritime (SHIP)/OUTPERFORM – Increasing Estimates; Raising PT to $17
Titan International (TWI)/OUTPERFORM – Noble Virtual Conference Highlights

Bit Digital (BTBT/$1.8 | Price Target: $5.5)
Joe Gomes jgomes@noblefcm.com | 561-999-2262
January Ethereum Metrics
Rating: OUTPERFORM

Data. Bit Digital reported its monthly Ethereum (“ETH”) treasury and staking metrics for the month of January 2026. As of month end, the Company held approximately 155,239 ETH versus 155,227 ETH at the end of December. Included in the ETH holdings were approximately 15,236 ETH and ETH-equivalents held in an externally managed fund. The Company’s total staked ETH was approximately 138,266, or about 89% of its total holdings as of January 31st.

Yield and Value. Staking operations generated approximately 344 ETH in rewards during the period, representing an annualized yield of approximately 2.9%. Based on a closing ETH price of $2,449, as of January 31, 2026, the market value of the Company’s ETH holdings was approximately $380.2 million.

Get the Full Report

Graham (GHM/$83.24)
Joe Gomes jgomes@noblefcm.com | 561-999-2262
FY3Q26 Results
Rating: MARKET PERFORM

Overview. For 3Q26, Graham delivered another strong quarter, with results supported by the timing of key project milestones, particularly within the defense business, along with contributions from new programs and continued growth across existing platforms.

3Q26 Results. Revenue increased 21% to $56.7 million, driven by solid performance across end markets. We were at $52.5 million. GM of 23.8% was below our 26.7% projections due to mix.  Adjusted EBITDA increased 50% to $6 million with an adjusted EBITDA margin of 10.7%. We had forecast $5.8 million. GHM reported adjusted net income of $3.5 million, or $0.31/sh, compared to our estimates of $3.0 million and $0..27/sh.

Get the Full Report

Seanergy Maritime (SHIP/$10.67 | Price Target: $17)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Increasing Estimates; Raising PT to $17
Rating: OUTPERFORM

Increasing Q4 and FY 2025 estimates. We have increased our FY 2025 revenue, adjusted EBITDA, and adjusted earnings per share (EPS) estimates to $157.0 million, $81.0 million, and $1.14, respectively, from $153.2 million, $77.9 million, and $1.07. Our full year estimates reflect higher fourth quarter revenue, adjusted EBITDA, and EPS of $48.3 million, $28.2 million, and $0.56, respectively, compared to our previous estimates of $44.5 million, $25.0 million, and $0.49. We are now forecasting fourth quarter and full year average time charter equivalent rates of $26,000 per day and $20,672 per day, versus prior forecasts of $23,900 and $20,147. We forecast fourth quarter and full year operating days of 1,800 and 7,163, respectively, compared to our prior estimates of 1,780 and 7,143.

Raising FY 2026 estimates. We have also increased our FY 2026 revenue, adjusted EBITDA, and adjusted EBITDA estimates to $176.2 million, $96.7 million, and $1.70, respectively, from $165.2 million, $89.1 million, and $1.44. We now forecast an average TCE rate of $24,063 compared to our previous estimate of $22,238.

Get the Full Report

Titan International (TWI/$11.06 | Price Target: $11)
Joe Gomes jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. We held a fireside chat with Titan CEO Paul Reitz at the Noble Virtual Conference. Highlights included the management changes, current market conditions, innovation, and tariffs. A rebroadcast is available at https://www.channelchek.com/videos/titan-international-twi-noble-capital-markets-virtual-conference-replay-february-2026.

Leadership Changes. In early December, Titan announced CFO David Martin transitioned into a new role as Chief Transformation Officer, while Tony Eheli, former Chief Accounting Officer, was named CFO. In the new CTO role, Mr. Martin will oversee the critical alignment of information technology, including the acceleration of AI adoption, along with human capital and risk management functions and initiatives.

Get the Full Report

Noble Capital Markets Research Report Friday, February 6, 2026

Companies contained in today’s report:

InPlay Oil (IPOOF)/OUTPERFORM – InPlay Broadens Capital Access with Israeli Bond Issuance
SelectQuote (SLQT)/OUTPERFORM – Solid Fiscal Q2 Execution but Carrier Pullback Creates Near-Term Pressure
The GEO Group (GEO)/OUTPERFORM – Thoughts on Current Environment

InPlay Oil (IPOOF/$10.97 | Price Target: $15.75)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
InPlay Broadens Capital Access with Israeli Bond Issuance
Rating: OUTPERFORM

Bond offering details. InPlay announced a senior unsecured bond issuance in Israel for up to 550 million New Israeli Shekels (NIS), or approximately C$241 million. Three amortization payments of 6% of the principal amount of the bonds will be due on December 15 of 2027, 2028, and 2029, and the fourth and last amortization payment of the remaining 82% will be due on December 15, 2030. The offering is expected to close on or around February 12, 2026, subject to certain conditions.

Expanding capital market access. Beyond the financing itself, we view the transaction as a strategic expansion of InPlay’s funding base outside of Canada. InPlay received interest from over 40 institutional investors in the oversubscribed offering and, to date, has accepted tenders for NIS 550 million of the bonds. The transaction further strengthens InPlay’s diversified financing sources while reducing its overall cost of capital.

Get the Full Report

SelectQuote (SLQT/$1.03 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Solid Fiscal Q2 Execution but Carrier Pullback Creates Near-Term Pressure
Rating: OUTPERFORM

Fiscal Q2 results. SelectQuote reported fiscal Q2 revenue of $537.1 million, above our $520.0 million estimate, driven by stronger-than-expected Senior performance. Adj. EBITDA of $84.7 million exceeded our $82.0 million forecast, reflecting near-record 39% adj. EBITDA margins in Senior that more than offset pharmacy reimbursement pressure.

Medicare Advantage headwinds. Management cited pressure from a large national carrier’s decision to reduce strategic marketing spend across all channels. We believe this reflects a deliberate effort to moderate enrollment growth and protect plan profitability following above-trend member additions, rather than any deterioration in underlying demand.

Get the Full Report

The GEO Group (GEO/$15.48 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Thoughts on Current Environment
Rating: OUTPERFORM

Environment. The current operating environment remains charged, as evidenced by the daily news. Nonetheless, we would point out that a key platform of the Trump Administration remains illegal immigration, and we do not expect that to change. Funding remains available under The One Big Beautiful Bill. And, historically, enforcement operations remain ongoing even in the face of a government shutdown.

Less New Awards Than Anticipated. The pace of new awards has been less than we had expected over the past few months. Whether this is just a temporary pause due to the significant number of new awards in 2025, the most recent new contract for GEO was the December skip tracing services contract worth up to $121 million of revenue over a two year period.

Get the Full Report

Noble Capital Markets Research Report Thursday, February 5, 2026

Companies contained in today’s report:

Lucky Strike Entertainment (LUCK)/OUTPERFORM – Event Business Turns A Corner

Lucky Strike Entertainment (LUCK/$7.33 | Price Target: $14.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Event Business Turns A Corner
Rating: OUTPERFORM

Q2 Results. The company reported revenue of $306.9 million, largely in line with our estimate of $310.0 million, while adj. EBITDA of $77.5 million, missed our estimate of $97.3 million by roughly 20%. Notably, the quarter was driven by increased investment, largely related to marketing, which supported top-line results while pressuring adj. EBITDA in the quarter.

Clear inflection point. The company reported same-store sales growth of 0.3%, while this figure may seem modest, we view it as a favorable development. Notably, the events business, which has been the primary drag on same-store sales in recent periods, improved significantly during the quarter and was roughly flat y-o-y. Furthermore, in January, the event business experienced double-digit growth before being impacted by a major snowstorm.

Get the Full Report

Noble Capital Markets Research Report Wednesday, February 4, 2026

Companies contained in today’s report:

Alliance Resource Partners (ARLP)/OUTPERFORM – Q4 and FY2025 Financial Results Exceed Expectations
Comstock (LODE)/MARKET PERFORM – Operational Update Following Webinar
Sky Harbour Group (SKYH)/OUTPERFORM – $150 Million Bond Pricing
The Beachbody Company (BODI)/OUTPERFORM – Executing Strategic Growth Initiatives
V2X (VVX)/OUTPERFORM – Some Recent News

Alliance Resource Partners (ARLP/$25 | Price Target: $33)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Q4 and FY2025 Financial Results Exceed Expectations
Rating: OUTPERFORM

Fourth quarter and full year 2025 financial results. Alliance reported adjusted fourth quarter revenue, adj. EBITDA and earnings per unit (EPU) of $535.5 million, $191.1 million, and $0.64, respectively, compared to $590.1 million, $124.0 million, and $0.12 during the prior year period. We had forecast revenue, adj. EBITDA and EPU of $560.1 million, $182.9 million, and $0.57, respectively. While the quarter was impacted by lower coal sales, which impacted revenue, operating expenses were lower, and net income on equity method investments exceeded our estimate. Full year 2025 adj. EBITDA and EPU of $698.7 million and $2.40, respectively, were above our estimates of $690.5 million and $2.33, respectively.

Management guidance for 2026. Total coal sales are expected to be in the range of 33.75 million to 35.25 million tons, while the sales price of coal per ton is expected to be in the range of $54.00 to $56.00. Segmented adjusted EBITDA expense per ton sold is expected to be $37.00 to $39.00. ARLP has committed and priced 32.2 million tons of its 2026 sales volume, including 30.5 million tons for the domestic market and 1.7 million tons for the export market.

Get the Full Report

Comstock (LODE/$2.94)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Operational Update Following Webinar
Rating: MARKET PERFORM

Industry-scale facility fully permitted. Comstock has received all required regulatory approvals for its first industry-scale solar recycling facility in Silver Springs, Nevada, including the Written Determination Permit and the Air Quality Permit from the Nevada Division of Environmental Protection. The permits cover the full scope required to commission a facility designed to process more than 3.0 million panels per year, representing up to 100 thousand tons of end-of-life solar materials. Installation, testing, and commissioning are expected to occur during the first quarter of 2026.

Unit economics. Comstock’s recycling process is certified as a zero-landfill solution and designed to handle all major solar panel types, eliminating contaminants and recovering aluminum, glass, and metal-rich tailings. Comstock estimates that facility-level economics reflect a combination of upfront processing fees and proceeds from recovered materials, resulting in revenue of ~$750 per ton against all-in operating costs of roughly $150 per ton. Based on current operating data, profitability is achievable at relatively low utilization levels.

Get the Full Report

Sky Harbour Group (SKYH/$9.31 | Price Target: $23)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
$150 Million Bond Pricing
Rating: OUTPERFORM

Pricing announced for upcoming bond issuance. Sky Harbour priced $150 million of Series 2026 private activity tax-exempt bonds at par to yield 6.0%, with a mandatory tender on January 1, 2031, and an expected closing on or about February 12, 2026. The transaction is another example of the company’s tax-advantaged financing toolkit and deepens its access to institutional municipal investors.

Deal upsized on strong investor demand. The transaction was initially marketed at $100 million but was upsized to $150 million after receiving approximately $450 million of orders from 18 institutional investors. In our view, the oversubscription supports growing investor comfort in the asset base, the cash flow ramp, and the repeatable development playbook.

Get the Full Report

The Beachbody Company (BODI/$11.65 | Price Target: $15)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Executing Strategic Growth Initiatives
Rating: OUTPERFORM

P90X Generation Next. On February 3, the company launched P90X Generation Next, the first new P90X fitness program in over a decade. Notably, the P90X franchise launched in 2005 and became one of the best-selling home fitness programs of all time, with more than 20 million people worldwide participating. Furthermore, the new exercise program is available on the company’s digital streaming platform BODi, and supported by brand partners and a new line of exercise supplements.

Digital streaming platform. Importantly, P90X Generation Next is available on the company’s digital platform, BODi, with a subscription. Moreover, subscribers can access the full P90X catalog of 145 workouts, including the original P90X, for $9.99/month. Additionally, the company offers a broader BODi membership priced at $19/month or an annual plan for $179/year  that includes 8,000+ workouts, 140+ step-by-step programs, and nutrition plans.

Get the Full Report

V2X (VVX/$66.4 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Some Recent News
Rating: OUTPERFORM

Recent News. There has been a flurry of positive recent news on V2X, from confirmation of the T-6 award to new partnerships with Amazon and Google to an award under the Missile Defense Agency’s (MDA) Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) to support Golden Dome to advancement to Phase II of the U.S. Army’s Flight School Next (FSN) competition. Below, we highlight three of the developments.

T-6 Award. The U.S. Court of Federal Claims denied the protest and upheld the Air Force’s selection of V2X for the $4.3 billion T-6 Contractor Operated and Maintained Base Supply (COMBS) contract. With a period of performance through July 2034, the $4.3 billion award could generate an average of $475 million in annual revenue.

Get the Full Report

Noble Capital Markets Research Report Monday, February 2, 2026

Companies contained in today’s report:

Eledon Pharmaceuticals (ELDN)/OUTPERFORM – Phase 1b Data Presented But Tegoprubart Remains Misunderstood
Kelly Services (KELYA)/OUTPERFORM – We Have Assumed Control
Resources Connection (RGP)/OUTPERFORM – More Cost Out

Eledon Pharmaceuticals (ELDN/$2.2 | Price Target: $10)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Phase 1b Data Presented But Tegoprubart Remains Misunderstood
Rating: OUTPERFORM

Phase 1b Data For Second Year After Transplantation Presented. Eledon presented data from its Phase 1b trial at the American Society of Transplant Surgeons (ASTS) meeting in January 2026. The presentation included data from 8 patients that had reached 24 months after transplantation, compared with 12 patients evaluated 12 months after transplantation presented in August 2025. These new data show a continued improvement in kidney function during the second year.

New Data Show Durability With Improvements. The 24-month data shows eGFR in tegoprubart patients continued to improve during months 12 to 24 after transplantation. The eGFR levels were restored to normal levels within 1 month after transplantation and were maintained for up to 2 years. Although this is a small number of patients, we see the result as consistent with prior data and our expectations for organ survival.

Get the Full Report

Kelly Services (KELYA/$10.79 | Price Target: $17)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
We Have Assumed Control
Rating: OUTPERFORM

Sale Completed. On Friday, Hunt Equity Opportunities, a subsidiary of Hunt Companies, acquired the 3,039,240 Class B shares previously held by the Terence E. Adderley Revocable Trust K. Hunt now has effective control of Kelly, as owner of 92.2% of the voting Class B shares. According to James Christopher Hunt, CEO of Hunt, “Hunt is very excited about the value creation opportunities ahead for Kelly. We look forward to supporting Chris Layden, CEO of Kelly, and the rest of the Company’s management team as they focus on accelerating growth and realizing Kelly’s full potential.”

Board Changes. As part of the transition, four Hunt designees have been named to Kelly’s Board, with five former Kelly directors leaving the Board, which will now consist of 8 members. Mr. Hunt has been named Chairman of the Board.

Get the Full Report

Resources Connection (RGP/$4.53 | Price Target: $10)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
More Cost Out
Rating: OUTPERFORM

Cost Out. Last week, RGP authorized a reduction of its global management and administrative workforce intended to reduce cost structure through enhanced efficiencies and streamlined operations. The Company expects the reduction in force to result in annual cost savings of $6-$8 million. Restructuring charges of approximately $3 million are expected to be recognized in the third and fourth quarters of fiscal 2026. The workforce reduction should be substantially completed by the end of fiscal 2026.

Additive. Last week’s announcement is on top of the October RIF, which also is expected to yield annual savings of $6 million to $8 million. Combined, the two actions could reduce expenses in the $12-$16 million range. These efforts are part of an even deeper assessment across the entire organization to streamline organizational structure, simplify processes, and adopt automation and AI to ensure RGP’s cost structure is adequately sized to the current revenue levels.

Get the Full Report

Noble Capital Markets Research Report Friday, January 30, 2026

Companies contained in today’s report:

1-800-Flowers.com (FLWS)/MARKET PERFORM – Leaning Into Its Efficiency Initiatives
AZZ (AZZ)/OUTPERFORM – Secular Tailwinds Expected to Sustain Sales and Cash Flow Growth
Unicycive Therapeutics (UNCY)/OUTPERFORM – OLC Resubmission Accepted For FDA Review

1-800-Flowers.com (FLWS/$4.63)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Leaning Into Its Efficiency Initiatives
Rating: MARKET PERFORM

Difficult quarter. Fiscal Q2 revenue of $702.2 million declined by a disappointing 9.5%, but was in line with our conservative estimate of $702.0 million. Adj. EBITDA was $98.1 million, beating our estimate of $89.5 million by 9.6%. In our view, the results reflect the company’s initiative to focus on efficient use of marketing spend. 

Cost actions are working, but benefits are not fully visible yet. Operating expenses declined meaningfully year over year, and the company has already achieved approximately $15 million in annualized run-rate cost savings. However, temporary consulting and incentive compensation costs related to the transformation are delaying the full earnings benefit. As these costs roll off, underlying profitability should improve.

Get the Full Report

AZZ (AZZ/$124.97 | Price Target: $140)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Secular Tailwinds Expected to Sustain Sales and Cash Flow Growth
Rating: OUTPERFORM

Updating estimates. While our FY2026 and FY2027 estimates are unchanged, we anticipate higher gross margins in the AZZ Metal Coatings and Precoat Metals segments beginning in FY2028. The company’s three-year plan established a goal of generating EBITDA margins of greater than 22.0% of revenue by 2028. Our revisions more closely align our forward estimates with this goal, and our estimates through FY2031 may be found in the financial model at the end of this report.

Secular growth drivers. We think AZZ is poised to benefit from multi-year secular drivers of growth. These include: 1) growth in infrastructure spending, 2) reshoring/nearshoring manufacturing, 3) migration to pre-painted steel and aluminum, 4) conversion from plastics to aluminum, 5) conversion to coil coating, and 6) growth in data centers. 

Get the Full Report

Unicycive Therapeutics (UNCY/$6.67 | Price Target: $60)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
OLC Resubmission Accepted For FDA Review
Rating: OUTPERFORM

Unicycive Announced FDA Acceptance Of The NDA. Unicycive announced FDA acceptance of its resubmission of the New Drug Application (NDA) for OLC (oxylanthanum citrate). The resubmitted application has been classified as a Class II complete response, with a six-month review period. June 29, 2026 is the new PDUFA date, the statutory date for the application to be answered. This is consistent with our expected timeframe for OLC approval and launch.

We See NDA Acceptance As A Significant Milestone. In June 2025, an FDA manufacturing inspection found compliance deficiencies at the facility of a contract manufacturer. This stopped the NDA approval process just weeks before the PDUFA (Prescription Drug User Fee Act) date of June 28, 2025. The review of the preclinical, clinical, safety, and manufacturing data had been completed. We believe this will result in prompt approval.

Get the Full Report

Noble Capital Markets Research Report Thursday, January 29, 2026

Companies contained in today’s report:

Alliance Resource Partners (ARLP)/OUTPERFORM – Upcoming FY 2025 Financial Results and 2026 Corporate Guidance
Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Updated Model; Raising Price Target
Hemisphere Energy (HMENF)/OUTPERFORM – 2026 Corporate Guidance Released, Revising Estimates

Alliance Resource Partners (ARLP/$24.31 | Price Target: $33)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Upcoming FY 2025 Financial Results and 2026 Corporate Guidance
Rating: OUTPERFORM

Fourth quarter and full year 2025 financial results. Alliance will report its fourth quarter and full year 2025 financial results before the market opens on Monday, February 2, 2026. Management will host an investor conference call and webcast the same day at 10:00 am ET. Along with the 2025 operational and financial results, we expect ARLP to release its 2026 corporate guidance and outlook.

Noble Estimates. We forecast fourth quarter 2025 revenue, EBITDA, and EPU of $560.1 million, $182.9 million, and $0.57, respectively. Our full year 2025 revenue, EBITDA, and EPU estimates are $2.2 billion, $690.5 million, and $2.33, respectively. Our fourth quarter EPU estimate reflects an expected unrealized and non-cash loss on the marked-to-market value of ARLP’s bitcoin holdings, which has no impact on our EBITDA estimate. We forecast 2026 revenue, EBITDA, and EPU of $2.3 billion, $700.5 million, and $2.65, respectively.

Get the Full Report

Great Lakes Dredge & Dock (GLDD/$15.32 | Price Target: $17)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Updated Model; Raising Price Target
Rating: OUTPERFORM

Updated Model. We tweaked our 4Q25 projections to include higher expected interest expense and the projected $3 million charge related to the payoff of the second lien term loan. As a result, our 4Q25 EPS estimate drops to $0.22 from a prior $0.26. The drop is not related to operational performance, and the debt swap will reduce overall interest expense going forward.

Cash Flow. With the completion of the new build program in early 2026, we expect Great Lakes to use the substantial free cash flow generation towards debt reduction. Over the past 5 years, capex has averaged $136 million annually. Roughly $25 million is for maintenance capex, and we do expect some additional capex as Great Lakes modernizes its fleet. Nonetheless, we estimate there should be at least $90 million on an annual basis for debt reduction.

Get the Full Report

Hemisphere Energy (HMENF/$1.53 | Price Target: $2.6)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
2026 Corporate Guidance Released, Revising Estimates
Rating: OUTPERFORM

Outlook for 2026. Hemisphere Energy released 2026 guidance outlining a C$12.0 million capital program, expected to support ~6.3% growth in average annual production to approximately 3,900 boe/d, compared to our estimated 2025 average of 3,670 boe/d. The capital program is expected to be fully funded from adjusted funds flow and is designed to provide disciplined year-over-year growth while protecting the balance sheet and maintaining shareholder returns. Production is expected to remain 99% heavy oil, supported primarily by polymer flood enhanced oil recovery at Atlee Buffalo.

Updating estimates. We are trimming our 2026 revenue estimate to C$89.9 million from C$93.7 million due to lower production and commodity price estimates. Our production and WTI crude oil price estimates are now 3,900 boe/d and US$60 compared to our previous estimates of 4,080 boe/d and US$65. Despite the lower revenue outlook, adjusted funds flow (AFF) increased modestly to C$40.0 million from C$39.7 million, reflecting lower assumed operating costs, improved differentials, and a reduced royalty burden. AFF per share remains unchanged at C$0.40.

Get the Full Report

Noble Capital Markets Research Report Wednesday, January 28, 2026

Companies contained in today’s report:

Cardiff Oncology (CRDF)/OUTPERFORM – Phase 2 Data Announced With Management Changes
Conduent (CNDT)/OUTPERFORM – New CEO Appointment
FAT Brands (FAT)/NOT RATED – Files Voluntary Chapter 11; Terminating Research Coverage
Kuya Silver (KUYAF)/OUTPERFORM – Letter of Intent to Purchase the Camila Processing Plant; Expansion Planned
Twin Hospitality (TWNP)/NOT RATED – Files Voluntary Chapter 11; Terminating Research Coverage

Cardiff Oncology (CRDF/$2 | Price Target: $12)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Phase 2 Data Announced With Management Changes
Rating: OUTPERFORM

Cardiff Made Two Significant Announcements. New data from the Phase 2 CRDF-004 trial testing onvansertib as a first line treatment for metastatic colorectal cancer was announced as expected. Patients in the high-dose onvansertib group showed a large benefit in overall response rates (ORR) and progression free survival (PFS). Separately, the CEO and CFO have left the company. Board Member Dr. Mani Mohindru was named Interim CEO.

Phase 2 Trial Design. As discussed in our January 5 report,CDRF-004 is a Phase 2 dose-finding trial testing two doses of onvansertib in combination with two standard-of-care (SOC) regimens against the standard of care regimens alone. It enrolled 110 patients with RAS-mutated metastatic colorectal cancer, mCRC. Its primary endpoint is objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), duration of response (DOR) and safety. These endpoints were selected to guide the design of Phase 3.

Get the Full Report

Conduent (CNDT/$1.61 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
New CEO Appointment
Rating: OUTPERFORM

Leadership transition at a natural inflection point. Conduent announced that Harsha V. Agadi has been appointed Chief Executive Officer, succeeding Cliff Skelton, with Margarita Paláu-Hernández named independent Chair of the Board. The change follows a multi-year period of portfolio rationalization, asset divestitures, and balance sheet repair. In our view, the move marks a clear emphasis on operational execution.

A shift toward speed and accountability. We view Agadi’s appointment as a logical next step for the company. His background includes senior operating and leadership roles across large, complex organizations such as Little Caesars, Church’s Chicken, Friendly’s, and Crawford & Company. We expect an early focus on leadership depth, decision velocity, and operational accountability, with an emphasis on accelerating the company’s return to revenue and cash flow growth. In our view, this signals a move from stabilization to performance.

Get the Full Report

FAT Brands (FAT/$0.26)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Files Voluntary Chapter 11; Terminating Research Coverage
Rating: NOT RATED

Chapter 11. Late Monday night, FAT Brands announced it has commenced voluntary chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of Texas. The Company plans to use the filings to deleverage the balance sheet, maximize value for its stakeholders, and support continued growth of its brands.

Precipitating Factor? It appears the tipping point for FAT to file the voluntary chapter 11 was Investor 352 Fund, the Company’s largest bondholder, earlier on Monday announcing it was suing FAT Brands for $109 million and promised Class B Common stock tied to ownership of Twin Peaks, as it was issued by Twin Hospitality.

Get the Full Report

Kuya Silver (KUYAF/$0.82 | Price Target: $3.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Letter of Intent to Purchase the Camila Processing Plant; Expansion Planned
Rating: OUTPERFORM

Processing plant acquisition. Kuya Silver signed a Letter of Intent (LOI) to purchase 100% of SMRL Camila, the company that owns the Camila conventional flotation plant, for US$7.8 million, subject to closing conditions. The Camila plant is currently processing Kuya Silver’s mineralized material to produce silver and other metal concentrates on a toll-milling basis. The plant is located on a key transport corridor between the Bethania mine and Lima, Peru, where concentrate is shipped to port. Execution of a definitive agreement is subject to the completion of legal, financial, environmental, and technical due diligence.

Scalable processing capacity. The Camila plant currently operates at 150 metric tonnes per day with plans to increase production capacity to 300 to 350 tonnes per day, which Kuya Silver expects to undertake after closing the acquisition. The expansion is projected to require an additional capital investment in the range of US$0.7 million to US$1.0 million.

Get the Full Report

Twin Hospitality (TWNP/$0.35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Files Voluntary Chapter 11; Terminating Research Coverage
Rating: NOT RATED

Chapter 11. Along with parent company FAT Brands, Twin Hospitality commenced voluntary chapter 11 proceedings in the  U.S. Bankruptcy Court for the Southern District of Texas. Twin Hospitality plans to use the filings to deleverage the balance sheet, maximize value for its stakeholders, and support the continued growth of its brands.

Precipitating Factor? It appears the tipping point for Twin Hospitality to file the voluntary chapter 11 was Investor 352 Fund, FAT Brands’ largest bondholder, earlier on Monday announcing it was suing FAT Brands for $109 million and promised Class B Common stock tied to ownership of Twin Peaks, as it was issued by Twin Hospitality. FAT Brands and Twin Hospitality are seeking joint administration of the Chapter 11 cases under the caption “In re FAT Brands Inc., et al.

Get the Full Report

Noble Capital Markets Research Report Tuesday, January 27, 2026

Companies contained in today’s report:

Graham (GHM)/MARKET PERFORM – Adds a Third Pillar

Graham (GHM/$76.25)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Adds a Third Pillar
Rating: MARKET PERFORM

An Acquisition. Graham has acquired FlackTek, a pioneer in advanced mixing and material processing solutions. The acquisition adds advanced materials processing as a third core platform for Graham, alongside Graham Manufacturing, specializing in vacuum & heat transfer, and Barber-Nichols, specializing in turbomachinery. FlackTek adds a proven and defensible product portfolio with a shared customer base and an installed footprint that extends across the full value chain, from upstream to downstream production and quality control.

Details. The purchase price is $35 million, which was paid 85% in cash and 15% using 75,818 GHM shares. There is a potential $25 million in future performance-based cash earnouts over 4 years based upon achieving progressively increasing adjusted EBITDA performance targets. The base purchase price is approximately 12x FlackTek’s projected 2026 adjusted EBITDA. FlackTek generates approximately $30 million in annualized revenue.

Get the Full Report

Noble Capital Markets Research Report Monday, January 26, 2026

Companies contained in today’s report:

The GEO Group (GEO)/OUTPERFORM – Expansion of Credit Facility

The GEO Group (GEO/$18.55 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Expansion of Credit Facility
Rating: OUTPERFORM

Credit Facility. The GEO Group amended its Credit Agreement, increasing GEO’s revolving credit facility to $550 million from a prior $450 million. The increase was effective as of January 20th. The increase provides the Company with additional financial flexibility, in our view, to further invest in growth opportunities and/or increase the share repurchase activity.

Share Repurchases. Recall, back in November, GEO announced an expansion of its share repurchase authorization to $500  million and extended the expiration date to  December 31, 2029. As of  November 6, 2025, the Company had approximately $458 million of repurchase authorization available under the share repurchase program. At the current price, the $100 million, if all used to repurchase shares, would further reduce the share count by approximately 5.38 million shares.

Get the Full Report

Noble Capital Markets Research Report Friday, January 23, 2026

Companies contained in today’s report:

Commercial Vehicle Group (CVGI)/OUTPERFORM – Some Green Shoots? Updated Estimates
Kuya Silver (KUYAF)/OUTPERFORM – Mine Development and Balance Sheet Strength Support 2026 Ramp-Up

Commercial Vehicle Group (CVGI/$1.63 | Price Target: $4)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Some Green Shoots? Updated Estimates
Rating: OUTPERFORM

Updated Estimates. We tweaked our fourth quarter 2025 estimates after speaking with management. The changes do not impact our belief in the investment case for Commercial Vehicle Group. We maintained our revenue estimate at $146 million. Gross margin has been lowered to 10.3% from 11% previously. We are now estimating an adjusted net loss of $5 million, or $0.15 per share. Adjusted EBITDA is now $2.8 million. For the full year, we are at revenue of $640.2 million and adjusted EBITDA of $18.3 million.

Green Shoots? Recent data from FTR and ACT could indicate an improved Class 8 truck environment in 2026, although we would need to see multiple months of positive developments before jumping in with both feet. According to FTR, December Class 8 truck orders of 42,200 units were the highest level since October 2022. Meanwhile, ACT raised its expectation for Class 8 production in 2026 to 246,000 units, up from a prior 205,000, and nearly flat with 2025.

Get the Full Report

Kuya Silver (KUYAF/$0.73 | Price Target: $3.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Mine Development and Balance Sheet Strength Support 2026 Ramp-Up
Rating: OUTPERFORM

Fourth Quarter Performance. The company mined 1,999 tonnes of mineralized material and processed 1,570 tonnes. Average processed grades were 6.0 oz/t silver (186.6 g/t), 1.40% lead, and 1.10% zinc, or 8.5 oz/t silver equivalent (264 g/t). Recoveries averaged 73.3% for silver, 79.1% for lead, and 57.1% for zinc. Metal processed included 7,724 ounces of silver, 18 tonnes of lead, and 15 tonnes of zinc. Sales included 5,441 ounces of silver, 15 tonnes of lead, and 8 tonnes of zinc, representing 6,194 silver-equivalent ounces, with silver contributing 88%. 

Private Placement Financing. Kuya closed a brokered private placement raising gross proceeds of C$25.5 million. The company intends to pursue either the acquisition of an operating plant near the mine or the construction of a plant at the Bethania site to vertically integrate silver concentrate production. As mine production expands toward the Phase 1 target of 350 tonnes per day, Kuya expects more consistent processing, improved silver recoveries, and the recovery of minor gold and copper currently lost in the toll-milling process.

Get the Full Report

Noble Capital Markets Research Report Wednesday, January 21, 2026

Companies contained in today’s report:

NN (NNBR)/OUTPERFORM – Adds a New Director
Power Metallic Mines Inc. (PNPNF)/OUTPERFORM – From Legacy Nickel to District-Scale Polymetallic System

NN (NNBR/$1.48 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Adds a New Director
Rating: OUTPERFORM

A Board Addition. NN added T ed White to its Board of Directors, effective immediately. Mr. White is co-founder of Legion Partners Asset Management, one of NN’s largest shareholders, owning approximately 9.55% of the outstanding common as of the date of the agreement, as well as economic exposure to another 5.99% of the Company’s shares.  Mr. White will join the Board’s Strategic Committee, which was formed to evaluate a broad range of strategic, financing, and other alternatives to enhance shareholder value.

Cooperation Agreement. In connection with this appointment, the Company entered into a cooperation agreement with  Legion Partners. The Legion cooperation agreement contains a customary standstill, voting commitment, and related provisions. Legion’s ownership is capped at 19.9% of the outstanding NNBR shares.

Get the Full Report

Power Metallic Mines Inc. (PNPNF/$1.17 | Price Target: $2.65)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
From Legacy Nickel to District-Scale Polymetallic System
Rating: OUTPERFORM

Initiating Coverage with an Outperform rating. Power Metallic Mines Inc. (OTCQB: PNPNF, TSXV: PNPN) is a Québec-based mineral exploration company advancing a high-grade polymetallic discovery that has evolved into a district-scale opportunity. Recent discoveries at the Nisk Project have shifted the investment thesis from a legacy nickel-sulphide asset to a high-grade copper-platinum group elements (PGE), nickel, gold, and silver system with emerging scale and continuity. Target metals, including copper, nickel, cobalt, platinum, and palladium, are integral to electrification, industrial manufacturing, and critical mineral markets. Our price target is US$2.65 per share or C$3.65 per share.

Lion Zone Discovery. The investment case is anchored by the Lion Zone, a high-grade, copper-dominant orthomagmatic polymetallic discovery that represents the core value driver within the broader Nisk land package. Drilling at Lion has returned exceptional grades, including 11.6 meters grading 8.3% copper, 9.6 g/t palladium, and 2.6 g/t platinum, materially enhancing the project’s value profile beyond nickel alone. Follow-up drilling at the nearby Tiger Zone has confirmed the presence of similar mineralization along trend, supporting the interpretation that Lion-style mineralization is repeatable rather than isolated.

Get the Full Report

Noble Capital Markets Research Report Tuesday, January 20, 2026

Companies contained in today’s report:

Information Services Group (III)/OUTPERFORM – AI Acquisition
Kratos Defense & Security (KTOS)/OUTPERFORM – A Strong Start to the Year

Information Services Group (III/$5.89 | Price Target: $6.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
AI Acquisition
Rating: OUTPERFORM

AI Maturity Index. Information Services Group has acquired the AI Maturity Index, a SaaS platform that allows organizations to assess the AI readiness of their workforces and improve their employees’ ability to leverage AI technology. The AI Maturity Index provides ISG with a high-impact, scalable entry point into every client’s AI journey. In its short time on the market, the AI Maturity Index has assessed more than 6,000 individual AI users and collected more than 400,000 data points—adoption that will expand exponentially as the platform gains broader use. Terms of the deal were not released.

Acceleration. The acquisition is part of a broader AI acceleration strategy by ISG that includes the formation of an AI Acceleration Unit that brings an integrated, expert-led approach to helping clients rapidly scale AI, and the upcoming launch of a proprietary insights platform with an AI-powered “intelligence advisor” to give organizations real-time access to highly sought-after ISG data and analysis.

Get the Full Report

Kratos Defense & Security (KTOS/$130.72 | Price Target: $145)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Strong Start to the Year
Rating: OUTPERFORM

Raising PT to $145. We are maintaining our Outperform rating and raising our price target on KTOS shares to $145 from a previous $95. KTOS shares are up 72% YTD, compared to 1.4% for the S&P 500, continuing the outperformance seen over the past three years. We believe the abundant opportunities across the business, potential positive increases in the defense budget, and solid execution present strong financial upside potential.

Defense Budget. Interest in the defense sector is partially being driven by the Trump Administration’s goal to increase the 2027 Defense budget by 50% to $1.5 trillion, up from approximately $1 trillion in 2026. Significantly, as relates to Kratos, a key focus of any increased spending will be on drones, autonomous systems, cybersecurity, and space, all key areas of Kratos.

Get the Full Report

Noble Capital Markets Research Report Friday, January 16, 2026

Companies contained in today’s report:

Alliance Entertainment Holding (AENT)/OUTPERFORM – Acquires Formidable Technology Company
CoreCivic, Inc. (CXW)/OUTPERFORM – Some Model Refinements
Ocugen (OCGN)/OUTPERFORM – Preliminary Phase 2 Data From OCU410 Shows Improvements in dAMD Geographic Atrophy

Alliance Entertainment Holding (AENT/$7.6 | Price Target: $11)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Acquires Formidable Technology Company
Rating: OUTPERFORM

Dynamic acquisition. On December 31, 2025, the company acquired Endstate, a technology company focused on NFC-enabled authentication, digital product identity, and authenticated resale infrastructure for physical goods. Following the acquisition, the company formed a new wholly owned subsidiary, Endstate Authentic LLC. Details of the acquisition were not disclosed.

Vinyl is just the start. Notably, the Endstate technology is currently used by Alliance Authentic for the sale of limited-edition, numbered, blockchain-authenticated vinyl records and a commission-based secondary marketplace that is expected to generate high-margin recurring revenue. Importantly, while the company currently only offers vinyl on this platform, we believe there is a significant opportunity for product category growth, given the company’s large selection of physical media and collectables.

Get the Full Report

CoreCivic, Inc. (CXW/$19.91 | Price Target: $28)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Some Model Refinements
Rating: OUTPERFORM

Model Refinements. Pre fourth quarter earnings, we went over our model and made some modest adjustments, as well as incorporated 2026 quarterly estimates. With the strong new contract awards in 2025, increased detention populations, and potential for additional awards in 2026, we believe CoreCivic is well positioned to post strong 2026 full year results.

Populations Continue to Rise. Overall, the ICE detainee population continues to increase, hitting just under 69,000 at year-end. This is up from approximately 39,000 at the end of 2024. We expect to see ICE detainee populations continue to increase over the course of 2026 as ICE brings on additional enforcement personnel. Increased populations bode well for CoreCivic.

Get the Full Report

Ocugen (OCGN/$1.62 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Preliminary Phase 2 Data From OCU410 Shows Improvements in dAMD Geographic Atrophy
Rating: OUTPERFORM

Positive Preliminary Data From The OCU410 Trial. Ocugen announced first data from its Phase 2 ArMaDa trial testing OCU410 in Geographic Atrophy associated with dry Age-related Macular Degeneration (GA-dAMD). The announcement included the patients who have reached 12 months after treatment, with 23 out of the total 51 patients enrolled. The data shows an overall 46% reduction in lesion growth compared with controls. We see this as a highly meaningful difference.

OCU410 Is A Single-Treatment Gene Therapy. OCU410 is being developed as gene therapy for patients with GA secondary to dry AMD. A single OCU410 intravitreal injection delivers RORA (retinoid-related orphan receptor alpha), a nuclear receptor that regulates key pathways involved in retinal homeostasis with four mechanisms of action.

Get the Full Report

Noble Capital Markets Research Report Thursday, January 15, 2026

Companies contained in today’s report:

Nicola Mining Inc. (HUSIF)/OUTPERFORM – Preparing for Growth: Expanding Milling Capacity

Nicola Mining Inc. (HUSIF/$0.72 | Price Target: $1.2)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Preparing for Growth: Expanding Milling Capacity
Rating: OUTPERFORM

Upsized Private Placement Financing. Due to strong support from shareholders and new institutional investors, Nicola Mining upsized its previously announced non-brokered private placement from C$1.0 million to C$3.0 million with the issuance of up to a total of ~3.3 million units at a price of C$0.90 per unit, including ~1.1 million issued during the first closing on the same terms. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of C$1.10 per share for a period of three years following the closing of the offering. The expiry of the warrants may be accelerated subject to certain conditions.

Use of Proceeds. Nicola’s Merritt Mill is the sole facility in British Columbia permitted to receive and process third-party gold and silver feed from across the province. Funds generated from the financing will be used for the purchase and installation of milling equipment to expand Merritt Mill processing capacity from ~200 tonnes per day to ~500 tonnes per day, the addition of a secondary ball mill, supplementary cleaner flotation cells, and associated pumping infrastructure. Spare bowl and mantle assemblies may be procured to support routine crusher maintenance and ensure operational reliability.

Get the Full Report

Noble Capital Markets Research Report Tuesday, January 13, 2026

Companies contained in today’s report:

Alliance Entertainment Holding (AENT)/OUTPERFORM – Another Exclusive Partnership
Kelly Services (KELYA)/OUTPERFORM – Trust To Sell Controlling Stake; Kelly Adopts Shareholders Rights Plan
ONE Group Hospitality (STKS)/OUTPERFORM – Releases Preliminary 4Q and FY25 Sales Results
SelectQuote (SLQT)/OUTPERFORM – Extended Maturities Enhances Balance Sheet Flexibility
SKYX Platforms (SKYX)/OUTPERFORM – Joining NVIDIA Connect

Alliance Entertainment Holding (AENT/$7.74 | Price Target: $11)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Another Exclusive Partnership
Rating: OUTPERFORM

Amazon MGM Studios partnership. Notably, on January 12, the company announced an exclusive multi-year home entertainment licensing agreement with Amazon MGM Studios Distribution. Furthermore, the partnership positions the company as the sole physical media distributor for Amazon MGM titles across DVD, Blu-ray, UHD/4K, and premium collector options in the U.S. and Canada.

Extensive catalog. Notably, Amazon MGM Studios has a number of favorable releases this year, including Fallout Season 2 and Mercy. Additionally, the new releases build on an extensive content catalog, which includes globally recognized franchises such as James Bond and Rocky, as well as several other popular titles, including The Silence of the Lambs and Legally Blonde.

Get the Full Report

Kelly Services (KELYA/$9.56 | Price Target: $17)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Trust To Sell Controlling Stake; Kelly Adopts Shareholders Rights Plan
Rating: OUTPERFORM

A Surprise Sale. Yesterday morning, Kelly Services announced that last Friday, the Terence E. Adderley Revocable Trust K notified Kelly’s Board that it entered into a definitive agreement to sell its entire holding, which constitutes 92.2% of the voting Class B common stock, to a private party. In an amended Schedule 13D filing after the market closed yesterday, the buyer was identified as Hunt Equity Opportunities.

A Large Premium. Hunt is purchasing the 3,039,940 B shares held by the Trust for $106 million, or the equivalent of $34.87/sh. The B shares closed on Friday at $8.86. Historically, the A and B shares have traded in tandem, although there have been periods in which one class has outpaced the other. There is a potential $15.2 million additional payout if the market capitalization of Kelly is equal to or greater than $1.2 billion at any time over the next 48 months. The deal is expected to close by the end of January.

Get the Full Report

ONE Group Hospitality (STKS/$2.46 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Releases Preliminary 4Q and FY25 Sales Results
Rating: OUTPERFORM

4Q25. Preliminary total GAAP revenues for 4Q25 are expected to be approximately $207 million, a 6.8% decrease from $222 million in 4Q24 and below the $223 million consensus estimate. This decline was primarily driven by RA Sushi and Kona Grill closures as part of the portfolio optimization and the change in the Company’s fiscal year. The Grill closures are expected to reduce total GAAP revenues by approximately 2.4%, representing 35% of the expected total GAAP revenue decline.

Calendar Impacts. The fiscal calendar change to 4 equal quarters in 2025 created timing differences that impacted quarterly comparisons: 4Q25 had 91 days versus 92 days in 4Q24. Additionally, the New Year’s Eve holiday shifted from fiscal 2025 to fiscal 2026. The exclusion of New Year’s Eve in the current year impacted total GAAP revenues by approximately 2.5%, representing 37% of the expected total GAAP revenue decline. Fourth quarter comparable sales are expected to decrease by approximately 1.8%.

Get the Full Report

SelectQuote (SLQT/$1.72 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Extended Maturities Enhances Balance Sheet Flexibility
Rating: OUTPERFORM

Extended maturity. The company completed a comprehensive refinance that extends its primary debt maturities to January 2031, removing the prior 2027 overhang. The new $325M senior secured term loan and $90M revolver replace the legacy structure and provide a multi-year runway. We view this as a structural reset that repositions the balance sheet to be better-aligned with the company’s long-term growth strategy.

Cost of capital improvements. The new facility delivers immediate interest savings on the revolver (SOFR + 400 bps versus SOFR + 500 bps previously) and embeds a clear path to lower term-loan pricing. The term loan begins at SOFR + 650 bps, with step-downs to SOFR + 600 bps and ultimately SOFR + 550 bps as leverage and Cash EBITDA improve. Operating performance will now have the potential to directly translate into interest savings.

Get the Full Report

SKYX Platforms (SKYX/$2.21 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Joining NVIDIA Connect
Rating: OUTPERFORM

NVIDIA partnership elevates SKYX’s technology profile. SKYX joined the NVIDIA Connect Program, gaining access to NVIDIA’s cloud and AI ecosystem to support development of its All-In-One Smart Platform. Management described the relationship as “game-changing,” reinforcing SKYX’s positioning as a technology platform company.

The Smart Platform is designed to be the ceiling-based hub of the home. The SkyPlatform embeds connectivity, safety, and intelligence into a single ceiling-based hub, combining Wi-Fi, voice and app control, speakers, thermostat functions, emergency lighting, and safety features. The platform is designed to be compatible with leading smart assistants such as Apple’s Siri and Amazon’s Alexa, simplifying how homes adopt and manage connected technology.

Get the Full Report

Noble Capital Markets Research Report Monday, January 12, 2026

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – All Permits Received for Comstock Metals’ Industry-Scale Recycling Facility
MustGrow Biologics Corp. (MGROF)/MARKET PERFORM – A Raise
V2X (VVX)/OUTPERFORM – A Board Refresh

Comstock (LODE/$3.74)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
All Permits Received for Comstock Metals’ Industry-Scale Recycling Facility
Rating: MARKET PERFORM

Receipt of Written Determination Permit. Comstock Metals received its Written Determination Permit from the Nevada Division of Environmental Protection for the processing of waste solar panels and photovoltaics at its planned industry-scale materials recovery facility in Silver Springs, Nevada. Receipt of the permit will result in a fully permitted operation and facility, and is expected to enable Comstock to install, test, and commission the facility on schedule during the first quarter of 2026.

Receipt of Air Quality Permit. Earlier this month, Comstock Metals received approval for the associated Air Quality control permit. Both permits represent the complete scope of required regulatory approvals for commissioning the scale up of a facility designed for processing more than 3.0 million panels per year representing up to 100 thousand tons per year of waste materials. The facility integrates technologies for crushing, conditioning, extracting, and recycling metal concentrates from photovoltaics.

Get the Full Report

MustGrow Biologics Corp. (MGROF/$0.4328)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Raise
Rating: MARKET PERFORM

Raise. MustGrow has announced a raise of up to $2 million in a non-brokered private placement of up to 4,000,000 units of the Company at a price of $0.50 per Unit. Each unit will consist of (i) one common share of the Company and (ii) one common share purchase warrant. Each whole warrant will be exercisable for a period of 60 months from the closing date and will entitle the holder to purchase one additional share at an exercise price of $0.70 per warrant share. The closing of the Offering is expected to take place on January 22, 2026, but may take place in one or more tranches, provided that the final tranche closing will occur no later than February 22, 2026.

Use of Proceeds. The Company intends to use the net proceeds raised from the LIFE Offering for inventory production for its mustard-derived organic biofertility product TerraSante, inventory for agricultural products to sell via its Canadian distribution platform NexusBioAg, and working capital and general corporate purposes. Recall,  MustGrow ran out of TerraSante product in the second and third quarters last year as demand exceeded management’s initial forecasts.

Get the Full Report

V2X (VVX/$62.78 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Board Refresh
Rating: OUTPERFORM

Refresh. V2X’s Board recently elected to increase the size of the Board from 7 members to 10 members and appointed Nicole B. Theophilus, Gerard A. Fasano, and Ross S. Niebergall, effective immediately, as new members of the Board to serve as Class I, Class II, and Class III Directors, respectively.

Theophilus. Ms. Theophilus currently serves as EVP and Chief Administrative Officer of Wabtec Corporation, a global provider of equipment, systems, digital solutions, and value-added services, since July 2024. She previously served as Wabtec’s EVP and Chief Human Resources Officer from August 2020 to March 2024. She was also the EVP and Chief Human Resources Officer for West Corporation from April 2016 to February 2018 and for ConAgra Foods from November 2009 to August 2015.

Get the Full Report

Noble Capital Markets Research Report Friday, January 9, 2026

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Third Quarter FY26 Review and Outlook
Direct Digital Holdings (DRCT)/MARKET PERFORM – Year End Review: 2026 Could Be A Pivotal Year
Resources Connection (RGP)/OUTPERFORM – Pricing Discipline Holds as Volume Pressure Persists

AZZ (AZZ/$117.04 | Price Target: $130)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Third Quarter FY26 Review and Outlook
Rating: OUTPERFORM

FY 2026 third-quarter financial results. AZZ reported adjusted net income of $46.0 million, or $1.52 per share, compared to $41.9 million, or $1.39 per share, during the prior year period. We had forecast adjusted net income of $44.9 million, or $1.48 per share. Compared to the third quarter of FY 2025, total sales increased 5.5% to $425.7 million. We had projected sales of $424.6 million. Gross margin of $101.9 million was modestly below our estimate of $103.2 million. Operating income of $69.5 million exceeded our estimate of $64.9 million, due to lower selling, general, and administrative expenses. Adjusted EBITDA increased modestly to $91.2 million compared to $90.7 million during the prior year period and our estimate of $93.3 million.

Updating estimates. With one quarter remaining, we have lowered our FY 2026 EBITDA estimate to $368.0 million from $369.2 million, and increased our EPS estimate to $6.03 from $5.98. We have increased our 2027 EBITDA and EPS estimates to $388.0 million and $6.60, respectively, from $387.4 million and $6.45. Our longer-term estimates through FY 2031 reflect multi-year growth and are summarized at the end of this report. Our estimates do not reflect the impact of acquisitions until announced.

Get the Full Report

Direct Digital Holdings (DRCT/$0.05)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Year End Review: 2026 Could Be A Pivotal Year
Rating: MARKET PERFORM

Direct Digital remained a key strategic channel, supporting customer acquisition, margin mix improvement, and first-party data ownership despite a challenging macro and media cost environment. The channel continued to evolve toward a full-funnel model, with increasing contribution from returning customers, improved conversion rates, and greater emphasis on retention and lifecycle engagement.

Repositioning for strategic growth. Ongoing headwinds from media cost inflation, intensifying competition, and platform volatility have persisted in 2025, prompting a strategic shift toward owned-channel development, tighter audience targeting, and stronger cross-functional execution. Looking forward, Direct Digital is increasingly aligned around a more disciplined growth model, prioritizing customer retention, lifetime value, and earnings durability over volume-driven top-line expansion.

Get the Full Report

Resources Connection (RGP/$4.5 | Price Target: $10)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Hans Baldau hbaldau@noblefcm.com |
Pricing Discipline Holds as Volume Pressure Persists
Rating: OUTPERFORM

Continued Revenue Pressure. RGP reported second quarter revenue of $117.7 million, down 19% year-over-year. On a same-day constant currency basis, revenue declined 18.4%, driven almost entirely by lower billable hours across the core On-Demand and Consulting segments. Importantly, the weakness remains volume-driven rather than price-driven, as average bill rates were largely stable and improved in several key geographies.

Pricing Discipline, Volume Weak. The Company continues to make progress with its value-based pricing initiatives. U.S. bill rates increased 2.5% year over year, Consulting bill rates rose 6.6%, and On-Demand bill rates increased 2.6%. However, these gains were more than offset by sharp declines in billable hours, particularly in Consulting (-33.8%) and On-Demand (-21.5%). Management specifically highlighted reduced demand for traditional finance roles as clients adopt automation and AI, underscoring that part of the On-Demand softness may be structural rather than purely cyclical.

Get the Full Report

Noble Capital Markets Research Report Thursday, January 8, 2026

Companies contained in today’s report:

ACCO Brands (ACCO)/OUTPERFORM – 2025 Review and 2026 Expectations
AZZ (AZZ)/OUTPERFORM – Third Quarter FY 2026 Results Outpace Expectations
Bit Digital (BTBT)/OUTPERFORM – Monthly ETH Production
Comstock (LODE)/MARKET PERFORM – Comstock Metals Achieves a Major Permitting Milestone

ACCO Brands (ACCO/$3.79 | Price Target: $9)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
2025 Review and 2026 Expectations
Rating: OUTPERFORM

2025 Review. ACCO Brands’ 2025 narrative was dominated by a clear priority: defend profitability and cash generation in a soft demand environment, using restructuring and cost takeout as the primary levers while the top line remained pressured. Across the first three quarters of 2025, demand was weak and uneven globally, and Q3 in particular underscored that as sales came in lower than expected; however, the Company still delivered adjusted earnings in line with its outlook by expanding gross margin and lowering SG&A, demonstrating meaningful operating discipline.

2026 Preview. Looking into 2026, we believe the key question for investors is whether ACCO can convert its 2025 operational progress into a durable and investable story rather than a purely defensive one. The most important variable remains organic revenue stabilization: the Company has demonstrated the ability to protect earnings despite sales declines, but the market will require evidence that declines are moderating, particularly in the Americas, and that channel inventories and promotional intensity are improving rather than worsening.

Get the Full Report

AZZ (AZZ/$109.83 | Price Target: $125)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Third Quarter FY 2026 Results Outpace Expectations
Rating: OUTPERFORM

FY 2026 third-quarter financial results. AZZ reported adjusted net income of $46.0 million, or $1.52 per share, compared to $41.9 million, or $1.39 per share, during the prior year period. We had forecast adjusted net income of $44.9 million, or $1.48 per share. Compared to the third quarter of FY 2025, total sales increased 5.5% to $425.7 million. We had projected sales of $424.6 million. Gross margin of $101.9 million was modestly below our estimate of $103.2 million. Operating income of $69.5 million exceeded our estimate of $64.9 million, due to lower selling, general, and administrative expenses. Adjusted EBITDA increased modestly to $91.2 million compared to $90.7 million during the prior year period and our estimate of $93.3 million. Adjusted EBITDA margin as a percentage of sales amounted to 21.4% compared to 22.5% during the third quarter of FY 2025.

Segment results. While Metal Coatings sales were up 15.7% compared to the prior year quarter, Precoat Metals sales were down 1.8%. Metal Coatings delivered higher sales due to increased volume driven by infrastructure-related projects in several end markets. Precoat Metals experienced lower sales due to weaker end markets, including building construction, HVAC, and transportation, partially offset by container. Segment adjusted EBITDA margin amounted to 30.3% for Metal Coatings and 19.7% for Precoat Metals.

Get the Full Report

Bit Digital (BTBT/$2.19 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Monthly ETH Production
Rating: OUTPERFORM

Data. Bit Digital reported its monthly Ethereum (“ETH”) treasury and staking metrics for the month of December 2025. As of December 31, 2025, the Company held approximately 155,227 ETH versus 154,398.7 ETH at the end of November. Included in the ETH holdings were approximately 15,146.0 ETH and ETH-equivalents held in an externally managed fund. The Company staked an additional 642 ETH during the month. The Company’s total staked ETH was approximately 138,263, or about 89% of its total holdings as of December 31st.

Yield and Value. Staking operations generated approximately 389.6 ETH in rewards during the period, representing an annualized yield of approximately 3.5%. Based on a closing ETH price of $2,967, as of December 31, 2025, the market value of the Company’s ETH holdings was approximately $460.5 million.

Get the Full Report

Comstock (LODE/$3.97)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Comstock Metals Achieves a Major Permitting Milestone
Rating: MARKET PERFORM

Receipt of Air Quality Permit. Comstock Metals received its Air Quality Permit from the Nevada Division of Environmental Protection – Bureau of Air Pollution Control for the processing of waste solar panels and photovoltaics at its planned industry-scale materials recovery facility in Silver Springs, Nevada. Receipt of the permit is expected to enable Comstock to install, test, and commission the facility on schedule during the first quarter of 2026.

Closing in on the Written Determination Permit. The Air Quality Permit follows a notification of eligibility for a written determination permit from the Nevada Division of Environmental Protection – Bureau of Sustainable Materials Management, which is now through the public notice period. Once the written determination permit is final, the two permits represent the complete scope of required regulatory approvals for commissioning the scale up of the recovery facility designed to process more than 3.0 million panels per year, representing up to 100 thousand tons per year of waste materials.

Get the Full Report

Noble Capital Markets Research Report Wednesday, January 7, 2026

Companies contained in today’s report:

Alliance Resource Partners (ARLP)/OUTPERFORM – Updating 2025 Estimates
First Phosphate Corp. (FRSPF)/OUTPERFORM – Transitioning from Exploration to Feasibility
Kuya Silver (KUYAF)/OUTPERFORM – Vertically Integrating its Operation

Alliance Resource Partners (ARLP/$23.73 | Price Target: $33)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Updating 2025 Estimates
Rating: OUTPERFORM

Updating 2025 estimates. We have lowered our Q4 and FY 2025 EPU estimates to $0.57 and $2.33, respectively, from $0.69 and $2.45. We have marked-to-market ARLP’s holding of bitcoins, which amounted to 568 bitcoins as of September 30. The price of bitcoin closed at $87,508.83 on December 31, 2025, compared to $114,056 on September 30. We anticipate the value of digital assets in Q4 2025 could decrease by approximately $15.1 million if all bitcoins were held through the fourth quarter. Because it would represent a non-cash unrealized loss, it has no impact on our adjusted EBITDA estimate. 

Looking ahead. While our 2026 and 2027 estimates are unchanged, we think coal supply and demand fundamentals could strengthen going into 2027, which could have a positive impact on pricing. Actions taken by the Trump Administration are expected to support and sustain coal-fired power generation. Electricity demand growth is expected to be driven by industrial growth, electrification, and the expansion of AI infrastructure and data centers.

Get the Full Report

First Phosphate Corp. (FRSPF/$0.76 | Price Target: $1.55)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Transitioning from Exploration to Feasibility
Rating: OUTPERFORM

Offtake agreement. First Phosphate recently amended an offtake agreement that includes a US$0.53 million upfront pre-payment during the fourth quarter of FY 2026. The funds will be used to advance the Begin-Lamarche project towards a feasibility study and later, production. The prepayment is subject to refund should First Phosphate decide not to pursue a feasibility study or production, neither of which we anticipate. In our view, the prepayment validates downstream interest and reinforces the strategic relevance of the Company’s integrated phosphate platform.

Final tranches of private placement. The Company closed the third and fourth tranches of its oversubscribed non-brokered private placement in December, raising approximately $9.6 million in gross proceeds and bringing total capital raised since June 2022 to approximately $49.7 million. Following recent warrant exercises and the offtake pre-payment, management indicates cash on hand of approximately $24 million, which we believe is sufficient to fund planned activities through 2026 and into 2027.

Get the Full Report

Kuya Silver (KUYAF/$0.7 | Price Target: $1.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Vertically Integrating its Operation
Rating: OUTPERFORM

Private Placement Financing. Kuya Silver Corporation (OTCQB: KUYAF, CSE: KUYA) announced a brokered private placement pursuant to the listed issuer financing exemption of up to 15.0 million units of the company at a price of C$1.00 per unit for aggregate gross proceeds of up to C$15.0 million. Each unit will consist of one common share and one half of one common share purchase warrant. Each warrant entitles the holder to purchase one common share at an exercise price of C$1.30 per common share for a period of 36 months from the date of issuance.

Use of Proceeds. Kuya intends to use the net proceeds of the offering to advance the company’s Bethania project with the acquisition of and/or development of concentrate processing capacity. Kuya is evaluating several options, each of which is fully permitted and will allow the company to vertically integrate its production capabilities. Funds may also be used to explore the Silver Kings Project in Ontario, discretionary growth capital, and for general corporate purposes.

Get the Full Report

Noble Capital Markets Research Report Tuesday, January 6, 2026

Companies contained in today’s report:

Gyre Therapeutics, Inc (GYRE)/OUTPERFORM – Hydronidone NDA Planned For 1H26, Meeting Expected Milestone

Gyre Therapeutics, Inc (GYRE/$7.92 | Price Target: $20)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Hydronidone NDA Planned For 1H26, Meeting Expected Milestone
Rating: OUTPERFORM

Positive Guidance Received From CDE. Gyre announced that its majority-owned subsidiary in China, Gyre Pharmaceuticals Ltd, has completed pre-NDA discussions with the Chinese Center for Drug Evaluation (CDE). The CDE indicated that the Phase 3 data meets the requirements for approval in chronic hepatitis B-associated liver fibrosis, as expected. An NDA submission is planned for 1H26, meeting our expected milestones for the product and the company.

Approval Would Allow Full Commercialization. Under the CDE regulations, the Phase 3 supports Conditional Approval for Hydronidone, allowing full commercialization. As part of the approval, company agrees to conduct a Phase 3c study after commercialization to confirm the effects seen in Phase 3. This is similar to a Phase 4 study in the US. The study design has not be finalized, although we expect similar endpoints for confirmation of the Phase 3 data.

Get the Full Report

Noble Capital Markets Research Report Monday, January 5, 2026

Companies contained in today’s report:

Cardiff Oncology (CRDF)/OUTPERFORM – Onvansertib Could Treat Colorectal Cancers That Escape Other Treatments
Vince Holding Corp. (VNCE)/OUTPERFORM – Emerging Growth Levers Provide Favorable 2026 View

Cardiff Oncology (CRDF/$2.66 | Price Target: $12)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Onvansertib Could Treat Colorectal Cancers That Escape Other Treatments
Rating: OUTPERFORM

Initiating Coverage With A $12 Price Target. Cardiff Oncology is developing onvansertib for the treatment of multiple cancer indications. Its lead program is in metastatic colorectal cancer for patients with a mutation that makes the cancer more aggressive and difficult to treat. This mutation, KRAS, is found in about 45% of the colorectal cancer patients. As a result of the mutation, several standard therapies are ineffective. We believe onvansertib’s unique mechanisms of action could be a breakthrough in cancer treatment.

Onvansertib Has Two Main Mechanisms of Action. Onvansertib inhibits PLK1, an intracellular protein needed for regulatory  functions that control cell growth and division. This protein can be overexpressed in many cancers, including colorectal cancer, overriding the normal controls. A second mechanism stops a pathway that allows tumors to survive in low oxygen environments and resist treatment with bevacizumab (Avastin).

Get the Full Report

Vince Holding Corp. (VNCE/$4.19 | Price Target: $5.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Emerging Growth Levers Provide Favorable 2026 View
Rating: OUTPERFORM

Execution inflection driven by digital and DTC momentum. 2025 marked a clear improvement in operating execution, led by stronger e-commerce performance, enhanced digital capabilities, and early traction from the dropship initiative, which collectively supported revenue growth and improved operating leverage.

Pricing power and profitability improved despite cost headwinds. The company demonstrated brand resilience through higher average selling prices, stable unit volumes, improved full-price sell-through, and disciplined cost management, allowing it to offset tariff and freight pressures and deliver meaningful adjusted EBITDA upside.

Get the Full Report

Noble Capital Markets Research Report Friday, January 2, 2026

Companies contained in today’s report:

ONE Group Hospitality (STKS)/OUTPERFORM – Development Update
Twin Hospitality (TWNP)/MARKET PERFORM – A Management Change
V2X (VVX)/OUTPERFORM – A Strong End to 2025 Awards

ONE Group Hospitality (STKS/$1.75 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Development Update
Rating: OUTPERFORM

Milestones. ONE Group announced a number of development milestones achieved during 4Q25. These include: entering into ten restaurant asset-light development agreements; an expanded footprint in large-market, professional sports & entertainment stadiums; opening two new STK locations; launching Benihana-branded retail product; and planning capital-efficient growth for 2026.

Largest Agreement. The ONE Group has entered into its largest asset-light development agreement in the Company’s history, securing development rights for a total of ten restaurants, either Benihana or Benihana Express locations, throughout the Greater San Francisco Bay Area. The two Benihana joint venture locations are expected to open in 2026, with the remaining franchised and licensed locations to open over the next seven years.

Get the Full Report

Twin Hospitality (TWNP/$0.67)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Management Change
Rating: MARKET PERFORM

Leadership Transition. Twin Hospitality announced Andy Wiederhorn has been named Chief Executive Officer of the Company and Roger Gondek has been named President of Twin Peaks, replacing former CEO and President Kim Boerema. While somewhat surprising, as Mr. Boerema was appointed CEO just this past May, the new leadership simplifies the leadership structure and optimizes resources while minimizing overhead, without any significant change in ability, in our view.

Roger Gondek. We believe the elevation of Mr. Gondek to President of Twin Peaks Restaurant to be the headline. Already serving as Chief Operating Officer of Twin Peaks since 2017, Mr. Gondek brings approximately 15 years of experience with the brand, including previous operations leadership roles with Twin Peaks’ largest franchisee. Mr. Gondek was the Executive Vice President of Operations of La Cima Restaurants, LLC, a franchiser of 43 Twin Peaks restaurants in Florida, Alabama, Georgia, South Carolina, North Carolina, and Tennessee, from June 2011 to July 2017. Prior to La Cima Restaurants, Mr. Gondek was a Divisional Vice President at Hooters of America from October 2001 to February 2011. Mr. Gondek has a deep understanding of Twin Peaks markets, in our opinion.

Get the Full Report

V2X (VVX/$54.55 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Strong End to 2025 Awards
Rating: OUTPERFORM

DMEA ATSP. V2X subsidiary Vertex Aerospace has been named as an awardee to the Defense Microelectronics Activity (DMEA) Advanced Technology Support Program (ATSP), according to the daily Department of War contract award activity. With multi-billion dollar potential, this award caps a strong year for V2X. The Company has won places on multiple billion dollar contracts, which bode well for the future.

Details. DMEA ATSP is an ID/IQ contract with a $23.357 billion ceiling. This multiple award contract has a base ordering period of five years with two option periods, three years and two years respectively, to establish a 10 year ordering period. There are a total of 10 awardees, including Vertex. As an ID/IQ, Vertex will need to compete for each award, but we are confident the Company will receive its fair share of wins under the contract.

Get the Full Report

Titan International (TWI) – Noble Virtual Conference Highlights


Monday, February 09, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble Virtual Conference. We held a fireside chat with Titan CEO Paul Reitz at the Noble Virtual Conference. Highlights included the management changes, current market conditions, innovation, and tariffs. A rebroadcast is available at https://www.channelchek.com/videos/titan-international-twi-noble-capital-markets-virtual-conference-replay-february-2026.

Leadership Changes. In early December, Titan announced CFO David Martin transitioned into a new role as Chief Transformation Officer, while Tony Eheli, former Chief Accounting Officer, was named CFO. In the new CTO role, Mr. Martin will oversee the critical alignment of information technology, including the acceleration of AI adoption, along with human capital and risk management functions and initiatives.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Seanergy Maritime (SHIP) – Increasing Estimates; Raising PT to $17


Monday, February 09, 2026

Seanergy Maritime Holdings Corp. is a prominent pure-play Capesize shipping company listed in the U.S. capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. The Company’s operating fleet consists of 18 vessels (1 Newcastlemax and 17 Capesize) with an average age of approximately 13.4 years and an aggregate cargo carrying capacity of approximately 3,236,212 dwt. Upon completion of the delivery of the previously announced Capesize vessel acquisition, the Company’s operating fleet will consist of 19 vessels (1 Newcastlemax and 18 Capesize) with an aggregate cargo carrying capacity of approximately 3,417,608 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Increasing Q4 and FY 2025 estimates. We have increased our FY 2025 revenue, adjusted EBITDA, and adjusted earnings per share (EPS) estimates to $157.0 million, $81.0 million, and $1.14, respectively, from $153.2 million, $77.9 million, and $1.07. Our full year estimates reflect higher fourth quarter revenue, adjusted EBITDA, and EPS of $48.3 million, $28.2 million, and $0.56, respectively, compared to our previous estimates of $44.5 million, $25.0 million, and $0.49. We are now forecasting fourth quarter and full year average time charter equivalent rates of $26,000 per day and $20,672 per day, versus prior forecasts of $23,900 and $20,147. We forecast fourth quarter and full year operating days of 1,800 and 7,163, respectively, compared to our prior estimates of 1,780 and 7,143.

Raising FY 2026 estimates. We have also increased our FY 2026 revenue, adjusted EBITDA, and adjusted EBITDA estimates to $176.2 million, $96.7 million, and $1.70, respectively, from $165.2 million, $89.1 million, and $1.44. We now forecast an average TCE rate of $24,063 compared to our previous estimate of $22,238.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Graham (GHM) – FY3Q26 Results


Monday, February 09, 2026

Graham Corporation designs, manufactures and sells critical equipment for the energy, defense and chemical/petrochemical industries. The Company designs and manufactures custom-engineered ejectors, vacuum pumping systems, surface condensers and vacuum systems. It is a nuclear code accredited fabrication and specialty machining company. It supplies components used inside reactor vessels and outside containment vessels of nuclear power facilities. Its equipment is found in applications, such as metal refining, pulp and paper processing, water heating, refrigeration, desalination, food processing, pharmaceutical, heating, ventilating and air conditioning. For the defense industry, its equipment is used in nuclear propulsion power systems for the United States Navy. The Company’s products are used in a range of industrial process applications in energy markets, including petroleum refining, defense, chemical and petrochemical processing, power generation/alternative energy and other.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. For 3Q26, Graham delivered another strong quarter, with results supported by the timing of key project milestones, particularly within the defense business, along with contributions from new programs and continued growth across existing platforms.

3Q26 Results. Revenue increased 21% to $56.7 million, driven by solid performance across end markets. We were at $52.5 million. GM of 23.8% was below our 26.7% projections due to mix.  Adjusted EBITDA increased 50% to $6 million with an adjusted EBITDA margin of 10.7%. We had forecast $5.8 million. GHM reported adjusted net income of $3.5 million, or $0.31/sh, compared to our estimates of $3.0 million and $0..27/sh.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bit Digital (BTBT) – January Ethereum Metrics


Monday, February 09, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Data. Bit Digital reported its monthly Ethereum (“ETH”) treasury and staking metrics for the month of January 2026. As of month end, the Company held approximately 155,239 ETH versus 155,227 ETH at the end of December. Included in the ETH holdings were approximately 15,236 ETH and ETH-equivalents held in an externally managed fund. The Company’s total staked ETH was approximately 138,266, or about 89% of its total holdings as of January 31st.

Yield and Value. Staking operations generated approximately 344 ETH in rewards during the period, representing an annualized yield of approximately 2.9%. Based on a closing ETH price of $2,449, as of January 31, 2026, the market value of the Company’s ETH holdings was approximately $380.2 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Weight Loss Drugs, Compounding, and the Legal Fight Shaping the GLP-1 Market

Weight-loss drugs have moved from niche medical treatments to mainstream consumer products. Television commercials, celebrity endorsements, and telehealth platforms have helped propel GLP-1–based therapies into the public consciousness — and into millions of medicine cabinets.

But as demand has surged, so have tensions across the healthcare, regulatory, and investment landscape.

That tension came sharply into focus today after Hims & Hers Health, Inc. (HIMS) shares fell more than 20% following news that Novo Nordisk has filed a lawsuit seeking to permanently block Hims from selling compounded versions of drugs that allegedly infringe on Novo’s patents — including versions tied to Wegovy, its blockbuster obesity treatment.

The dispute highlights a broader reckoning underway in the fast-growing — and fast-changing — obesity drug market.


A Market Built on Demand — and a Regulatory Loophole

GLP-1 drugs such as Wegovy (Novo Nordisk) and Zepbound/Mounjaro (Eli Lilly) have reshaped expectations around medical weight loss. Unprecedented demand led analysts to project a global obesity drug market of $150 billion to $200 billion by the early 2030s.

But demand quickly ran into supply constraints, high prices, and limited insurance coverage. That gap created an opening for compounded versions of GLP-1 drugs — products mixed by pharmacies and prescribed on a case-by-case basis under the Federal Food, Drug, and Cosmetic Act.

Under U.S. law, compounding is permitted in limited circumstances, such as:

  • When a patient cannot tolerate an ingredient in a branded drug
  • When a specific dosage or formulation is medically necessary
  • When an FDA-approved drug is in short supply

Novo has estimated that as many as 1.5 million Americans are currently using compounded GLP-1 drugs.

Telehealth companies like Hims moved aggressively into this space, marketing lower-cost alternatives to branded therapies — often directly to cash-pay consumers.


Novo vs. Hims: From Tension to Litigation

Novo Nordisk’s lawsuit represents a major escalation.

The company is asking the court to:

  • Permanently ban Hims from selling compounded versions of its drugs
  • Recover damages for alleged patent infringement

Novo argues that Hims’ compounded products contain semaglutide, the active ingredient in Wegovy, which is protected by U.S. patents through 2032. Importantly, Novo has stated that semaglutide is no longer in short supply in the U.S. — undermining one of the key legal justifications for compounding.

Hims, for its part, has argued that its products are legal because they are “personalized” in dosage. The company had planned to offer an oral obesity pill for as little as $49 for the first month, roughly $100 less than Novo’s approved Wegovy pill.

However, the pressure intensified last week when:

  • Hims said it would stop offering its newly launched obesity pill copycat
  • The FDA announced it planned to take legal action against Hims
  • Federal regulators said they would restrict access to GLP-1 ingredients used in non-approved compounded drugs
  • The FDA indicated it may refer the matter to the Department of Justice over potential violations of federal law

In a public statement, Hims called Novo’s lawsuit “a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care,” accusing Big Pharma of weaponizing the U.S. judicial system to limit consumer choice.


FDA Scrutiny Raises the Stakes

The FDA has made clear it is increasingly concerned about the quality, safety, and legality of compounded GLP-1 products.

Unlike branded drugs:

  • Compounded drugs are not FDA-approved
  • They have not undergone clinical trials to demonstrate efficacy
  • Oversight is more fragmented

According to legal experts, potential FDA enforcement actions could include:

  • Warning letters
  • Court injunctions (with DOJ involvement)
  • Administrative seizure of products

Novo and Eli Lilly have both taken aggressive steps over the past two years to crack down on compounding pharmacies and marketers. Novo has reportedly filed around 130 lawsuits related to deceptive marketing practices and consumer fraud, while Lilly has pursued similar actions tied to tirzepatide, its active ingredient.


Investors Reassess the Obesity Drug Opportunity

Beyond the immediate legal headlines, the episode underscores a broader shift in how Wall Street views the obesity drug market.

While demand remains strong, expectations around pricing power and long-term market size are being recalibrated:

  • Forecasts for the global obesity market have fallen roughly 30%, to around $100 billion by 2030
  • The once-common $150 billion target has been pushed out to 2035 by some analysts
  • Jefferies recently cut its peak market estimate by 20%, projecting a peak of $80 billion

As Jefferies analyst Michael Leuchten put it: “That $150 billion pie is gone, even if you’re very bullish on volumes.”

Competition is intensifying as well. Novo and Lilly remain the dominant players, but falling U.S. prices, the expected entry of new drugs, and eventual generic competition are reshaping the outlook — particularly in the cash-pay consumer segment.


What This Means Going Forward

For consumers, the crackdown on compounding could limit access to lower-cost alternatives — at least in the near term.

For telehealth companies, the legal and regulatory risks around drug development and distribution are becoming harder to ignore.

And for investors, the GLP-1 market is entering a new phase: one where growth remains substantial, but margins, market share, and timelines are far less certain than they appeared just a year ago.

The obesity drug boom is real. But as the fight between Novo Nordisk, Hims, the FDA, and regulators shows, the path forward will be shaped as much by courts and policymakers as by science and demand.

Transocean to Acquire Valaris in $5.8 Billion All-Stock Offshore Drilling Merger

Transocean Ltd. (NYSE: RIG), a leading international provider of offshore contract drilling services, announced today that it has entered into a definitive agreement to acquire Valaris Limited (NYSE: VAL) in an all-stock transaction valued at approximately $5.8 billion. The transaction creates one of the largest and most diversified offshore drilling companies in the world, with a pro forma enterprise value of approximately $17 billion.

Under the terms of the agreement, Valaris shareholders will receive a fixed exchange ratio of 15.235 shares of Transocean stock for each Valaris common share. Based on the companies’ closing prices on February 6, 2026, Transocean shareholders will own approximately 53% of the combined company on a fully diluted basis, with Valaris shareholders owning the remaining 47%.

A Strategic Combination of Premium Offshore Assets

Transocean is widely recognized for operating the highest-specification floating offshore drilling fleet in the world, with a strong focus on ultra-deepwater and harsh-environment drilling. The company currently owns or operates a fleet of 27 mobile offshore drilling units, including 20 ultra-deepwater floaters and seven harsh-environment floaters.

Valaris brings complementary strengths, operating a high-quality fleet of ultra-deepwater drillships, versatile semisubmersibles, and modern shallow-water jackups. With operations spanning nearly every major offshore basin globally, Valaris has established itself as an industry leader across all water depths and geographies, emphasizing safety, operational excellence, and technological innovation.

On a pro forma basis, the combined company will own 73 rigs, including 33 ultra-deepwater drillships, nine semisubmersibles, and 31 modern jackups, significantly expanding its ability to serve customers in deepwater, harsh-environment, and shallow-water markets worldwide.

Financial and Operational Benefits

The transaction is expected to deliver substantial financial and operational benefits. The combined company will have an industry-leading contract backlog of approximately $10 billion, enhancing cash flow visibility and providing a strong foundation for long-term planning.

Transocean has identified more than $200 million in incremental cost synergies related to the transaction, additive to its ongoing cost-reduction program, which is expected to reduce costs by more than $250 million in aggregate through 2026. Management expects the stronger pro forma cash flow to accelerate debt reduction, targeting a leverage ratio of approximately 1.5x within 24 months of closing.

“This transaction creates a very attractive investment in the offshore drilling industry, differentiated by the best fleet, proven people, leading technologies, and unequalled customer service,” said Keelan Adamson, Transocean’s President and Chief Executive Officer. “The powerful combination is well-timed to capitalize on an emerging, multi-year offshore drilling upcycle.”

The combined company is expected to have an estimated pro forma market capitalization of approximately $12.3 billion, improved trading liquidity, and a stronger capital markets profile, potentially enabling broader equity index inclusion.

Leadership and Transaction Structure

Following the close of the transaction, Transocean’s senior management team will continue to lead the combined company, with Keelan Adamson serving as Chief Executive Officer. Jeremy Thigpen will assume the role of Executive Chairman of the Board. The board will consist of nine current Transocean directors and two current Valaris directors.

Transocean will remain incorporated in Switzerland, with its primary administrative office in Houston. Valaris Limited is a Bermuda exempted company, and the transaction will be completed through a court-approved scheme of arrangement under Bermuda’s Companies Act.

The transaction has been unanimously approved by the boards of directors of both companies and is expected to close in the second half of 2026, subject to regulatory approvals, customary closing conditions, and approval by shareholders of both companies. Shareholder support agreements have already been secured from Perestroika AS, which owns approximately 9% of Transocean’s outstanding shares, and from Famatown Finance Limited and Oak Hill Advisors, which collectively own approximately 18% of Valaris’ outstanding shares.

Industry Context and Recent Trends

The offshore drilling industry has been undergoing a period of consolidation following years of financial stress, bankruptcies, and asset rationalization. In recent years, the number of offshore drillers operating globally has declined sharply, leaving a smaller group of companies with increasingly high-quality fleets.

At the same time, energy producers have become more disciplined with capital spending, prioritizing returns over aggressive production growth. This has favored offshore projects with long reserve lives and lower decline rates, particularly in deepwater basins such as the Gulf of Mexico, Brazil, and offshore West Africa.

Oilfield service providers, including offshore drillers, have increasingly pursued mergers to improve scale, reduce costs, and enhance pricing power amid ongoing operational and pricing pressures. As available high-specification rigs remain constrained, leading contractors have been better positioned to benefit from improving dayrates and utilization.

Against this backdrop, the Transocean–Valaris combination reflects a broader industry trend toward creating larger, financially stronger players capable of supporting complex offshore developments while delivering improved returns to shareholders.

Noble Capital Markets Emerging Growth Virtual Equity Conference – February 2026 – Presenting Company Replays

Participating Companies

Day 1 Replays

Day 2 Replays

Participating in 1×1 Meetings Only

Release – Newsmax Announces Crypto Plan for Asset Reserve

Research News and Market Data on NMAX

October 16, 2025

Company’s Board Authorizes Strategic Purchases of up to $5 Million of Bitcoin and Trump Coin

BOCA RATON, FL / ACCESS Newswire / October 16, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced that the Company’s Board of Directors has authorized a strategic purchase plan of up to $5 million to purchase Bitcoin and Trump Coin over the next 12 months, subject to market conditions.

Newsmax expects to join more than 100 public companies that hold Bitcoin or other cryptocurrencies on their balance sheets. According to BitcoinTreasuries data, public company-held coin represents over 4.7% of total Bitcoin in circulation.

Newsmax also plans to add official Trump Coin to its strategic crypto reserve. The popular meme coin was launched earlier this year by President Trump and the circulating coin value exceeds $1.2 billion today with a total coin market value of around $6 billion, according to figures from Coinbase.

“Bitcoin is fast becoming the gold standard of cryptocurrency, and we believe it would be an important company marker to add this asset to our company reserves,” Newsmax CEO Christopher Ruddy said.

“We are also excited to add Trump Coin to our cryptocurrency plan, as we believe the coin’s value should track the success of the Trump presidency, which so far has been impressive,” Ruddy continued.

After making such a purchase, Newsmax expects to be the first NYSE company to purchase Trump Coin.

Newsmax anticipates making the first tranche of cryptocurrency purchases in the near future. Additional cryptocurrency acquisitions will be evaluated based on market conditions, operational requirements and strategic objectives. The Company maintains flexibility to adjust its digital asset strategy as market conditions evolve.

Newsmax has established comprehensive protocols for digital asset custody and management, partnering with leading institutional cryptocurrency services providers to ensure secure storage and handling of its cryptocurrency reserves.

This past March, President Trump announced the establishment of a Strategic Bitcoin Reserve for the United States. The fund is expected to begin with forfeited government Bitcoin and will grow with a Digital Asset Stockpile made up of other cryptocurrencies.

Newsmax listed on the NYSE in March 2025 after a historic Private Preferred raise and Regulation A+ IPO offering that successfully raised $300 million.

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major cable stations, as well as a major satellite system. Newsmax’s media properties reach more than 40 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches 20 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

Forward-Looking Statements

This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited to our ability to change the direction of Newsmax, our ability to keep pace with new technology and changing market needs, the competitive environment of our business changes in domestic and global general economic and macro-economic conditions and/or uncertainties and factors set forth in the sections entitled “Risk Factors” in Newsmax’s Annual Report on Form 10-K for the twelve months ended December 31, 2024, Newsmax’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

Investor Contacts

Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

Release – NN, Inc. to Hold Third Quarter 2025 Earnings Conference Call on Thursday, October 30, 2025

Research News and Market Data on NNBR

CHARLOTTE, N.C., Oct. 16, 2025 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, announced today that it will release its third quarter 2025 financial results for the period ended September 30th, 2025, after the close of the market on Wednesday, October 29th, 2025. The Company will hold a related conference call on Thursday, October 30th, 2025, at 9:00 a.m. E.T. Participants on the call are asked to register five to ten minutes prior to the scheduled start time by dialing 1-877-255-4315 and from outside the U.S. at 1-412-317-6579.

The conference call will be webcast simultaneously and in its entirety through the NN, Inc. Investor Relations website. Shareholders, media representatives and others may participate in the webcast by registering through the Investor Relations section on the company’s website at https://investors.nninc.com/.

For those who are unavailable to listen to the live call, a replay will be available shortly after the call on NN’s website through October 31st, 2026.

About NN, Inc.
NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and Asia. For more information about the company and its products, please visit www.nninc.com.

Investor Relations:
Joe Caminiti or Stephen Poe
NNBR@alpha-ir.com
312-445-2870

Source: NN, Inc.

Release – ACCO Brands Corporation Announces Third Quarter 2025 Earnings Webcast

Research News and Market Data on ACCO

10/17/2025

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that it will release its third quarter 2025 earnings after the market close on October 30, 2025. The Company will host a conference call and webcast to discuss the results on October 31 at 8:30 a.m. EST. The webcast can be accessed through the Investor Relations section of www.accobrands.com and will be available for replay.

About ACCO Brands Corporation

ACCO Brands is the leader in branded consumer products that enable productivity, confidence and enjoyment while working, when learning and while playing. Our widely recognized brands include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found atwww.accobrands.com.

For further information:

Chris McGinnis
Investor Relations
(847) 796-4320

Kori Reed
Media Relations
(224) 501-0406

Source: ACCO Brands Corporation

Release – Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Research News and Market Data on TNXP

NX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox

TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple preclinical models

Data support advancement of TNX-801 toward clinical development

CHATHAM, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”) presented data in an oral presentation at the World Vaccine Congress–Europe 2025, held October 14–16, 2025, in Amsterdam, the Netherlands. A copy of the Company’s presentation, titled “Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine,” is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

“Vaccines remain a cornerstone of pandemic preparedness and biodefense,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “The data presented in Amsterdam support the potential of TNX-801 as a next-generation orthopoxvirus vaccine candidate with the ability to confer durable protection. We believe TNX-801 has the potential to strengthen global readiness for emerging and re-emerging poxvirus threats.”

TNX-801 is a live, attenuated, minimally replicative investigational vaccine candidate based on horsepox virus and is being developed to protect against mpox (monkeypox) and smallpox. Preclinical data presented by Sina Bavari, Ph.D., Executive Vice President, Infectious Disease Research at Tonix Pharmaceuticals, demonstrated that TNX-801 produced durable immune protection following a single dose and was well tolerated across multiple routes of administration, including percutaneous, subcutaneous, and intramuscular delivery. TNX-801 elicited strong neutralizing antibody responses and protected animals from clinical disease and mortality following mpox challenge in non-human primate, rabbit, and murine models. Immunogenicity and durability were observed for at least 14 months post-vaccination.

“We are encouraged by the consistency and durability of the TNX-801 data across multiple preclinical models,” said Dr. Sina Bavari. “We are also excited by the opportunity to evaluate microneedle patch technology as a novel delivery platform to simplify administration and expand vaccine accessibility in future development stages.”

About TNX-801*
TNX-801 (recombinant horsepox virus) is an, attenuated, minimally replicative, live virus vaccine based on horsepox in pre-clinical development to prevent mpox and smallpox. Tonix reported positive preclinical efficacy data, demonstrating that TNX-801 vaccination protected non-human primates against lethal challenge with monkeypox. After a single dose vaccination, TNX-801 prevented clinical disease and lesions and decreased shedding in the mouth and lungs of non-human primates. The findings are consistent with mucosal immunity and suggest the ability to block forward transmission, similar to Dr. Edward Jenner’s vaccine, which eradicated smallpox and kept mpox out of the human population. TNX-801 is based on synthesized horsepox which is believed to be more closely related to Dr. Jenner’s vaccine than 20th century vaccinia viruses. Smallpox vaccines descended from Jenner’s vaccine used prior to 1900 would be called horsepox by modern nomenclature.. Tonix has received official written response from a Type B pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) to develop TNX-801 as a potential vaccine to protect against mpox disease and smallpox. Tonix has announced a collaboration with the Kenya Medical Research Institute (KEMRI) to design, plan and seek regulatory approval for a Phase I clinical study of TNX-801 in Kenya. The Company believes TNX-801 has the potential to make a global impact on mpox and the risk of smallpox because of its durable T-cell immune response, the potential to manufacture at scale, and the use of a lower dose than non-replicating vaccines. The FDA-approved non-replicating mpox vaccine Jynneos® requires two doses and provides a relatively short duration of protection. FDA also recently approved ACAM2000, a live, replicating vaccinia vaccine for prevention of mpox. ACAM200 is a clone from DryVax®, a 20th century vaccinia vaccine derived from the NYCBH strain. Pre-clinical results from an mRNA vaccine recently showed some protection from a Clade I monkeypox challenge, but with multiple break-through lesions in vaccinated animals.

Tonix Pharmaceuticals Holding Corp.*
Tonix Pharmaceuticals is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. Tonix has received FDA approval for TonmyaTM, a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. This marks the first approval for a new prescription medicine for fibromyalgia in more than 15 years. Tonix also markets two treatments for acute migraine in adults. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a monoclonal antibody for the seasonal prevention of Lyme Disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize Tonmya and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris 
Tonix Pharmaceuticals 
investor.relations@tonixpharma.com 
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
brian.korb@astrpartners.com 

Media Contact 
Ray Jordan 
Putnam Insights 
ray@putnaminsights.com 

INDICATION
TONMYA is indicated for the treatment of fibromyalgia in adults.
CONTRAINDICATIONS
TONMYA is contraindicated:
In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.
With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.
During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.
In patients with hyperthyroidism.
WARNINGS AND PRECAUTIONS
Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.
Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.
Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.
Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.
CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.
Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.

DRUG INTERACTIONS

MAO inhibitors: Life-threatening interactions may occur.
Other serotonergic drugs: Serotonin syndrome has been reported.
CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.
Tramadol: Seizure risk may be enhanced.
Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.
USE IN SPECIFIC POPULATIONS
Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).
Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.
Pediatric use: The safety and effectiveness of TONMYA have not been established.
Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.
Please see additional safety information in the full Prescribing Information.
To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: Tonix Pharmaceuticals Holding Corp.